Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.23M$1.23Mderived+8.1% vs Q4 2024 Net Income-$1.22M-$1.22MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$150,775N/M Operating Incomederived-$1,200,195N/M Operating Cash Flowderived$151,990−36.3% Free Cash Flowderived$151,536−30.8% Margins · derivedGross margin12.3%+26.5 pt vs Q4 2024
Operating margin-97.9%+7.6 pt vs Q4 2024
Net margin-99.7%+8.3 pt vs Q4 2024
ended Dec 31, 2025 · filed Apr 1, 2026 · 91 d after period end